Table 4.
Demographic and clinical characteristics of patients in the prospective study (n=170)
| Clinical Data | N (%) | Positive by either GI Panel N (%) |
|---|---|---|
| Median age (range) | 54.5 (3–86) | n/a |
| Pediatric patients (<18 years) | 20 (11.8) | 16 (80.0) |
| Sex, female | 93 (54.7) | 36 (34.6) |
| Hematologic malignancies/HSCT | 87 (51.2) | 41 (47.1) |
| Solid tumor (e.g. Lung cancer) | 83 (48.8) | 31 (37.3) |
| Outpatient | 50 (29.4) | 25 (50) |
| Inpatient | 120 (70.6) | 47(39.1) |
| Intensive care unit | 21 (17.5) | 3 (9.5) |
| Mortality (30 days) | 10 (5.9) | 2 (20.0) |
| Length of stay (days), median (95%CI) | 11.5 (8–17) | 6 (4–14) |
| Diarrhea | 133 (78.5) | 57 (43) |
| WBC count (109/L), mean ± SD | 6.8 ± 7.1 | n/a |
| Colitis on imaging | 8 (4.7) | 5 (62.5) |
| GI GVHD | 11 (6.5) | 6 (54.5) |
| Antibiotics within 30 days | 85 (50) | 39 (39.0) |
| Chemotherapy within 30 days | 87 (51.5) | 33 (37.9) |
*
GI: Gastrointestinal; HSCT: Hematopoietic Stem Cell Transplant; GVHD: Graft versus Host Disease; WBC: White Blood Cells